ContextVision
Market Cap
kr767.8m
Last Updated
2020/02/18 20:48 UTC
Data Sources
Company Financials +
Executive Summary
ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with high growth potential.
Share Price & News
How has ContextVision's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: COV has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0%
COV
0.8%
NO Healthcare Services
-0.3%
NO Market
1 Year Return
67.2%
COV
9.3%
NO Healthcare Services
-1.2%
NO Market
Return vs Industry: COV exceeded the Norwegian Healthcare Services industry which returned 8.8% over the past year.
Return vs Market: COV exceeded the Norwegian Market which returned -1.3% over the past year.
Shareholder returns
| COV | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 0.8% | -0.3% |
| 30 Day | 2.0% | -1.1% | -3.6% |
| 90 Day | 13.0% | 4.6% | 2.2% |
| 1 Year | 67.2%67.2% | 10.7%9.3% | 4.2%-1.2% |
| 3 Year | 107.0%107.0% | 25.7%21.0% | 29.6%13.1% |
| 5 Year | 376.2%376.2% | 87.9%76.3% | 55.9%20.5% |
Price Volatility Vs. Market
How volatile is ContextVision's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
How Much Of ContextVision AB (publ) (OB:COV) Do Insiders Own?1 month ago | Simply Wall St
Here's Why We Don't Think ContextVision's (OB:COV) Statutory Earnings Reflect Its Underlying Earnings Potential2 months ago | Simply Wall St
Introducing ContextVision (OB:COV), The Stock That Zoomed 284% In The Last Five YearsValuation
Is ContextVision undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: COV (NOK100) is trading below our estimate of fair value (NOK588.44)
Significantly Below Fair Value: COV is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: COV is poor value based on its PE Ratio (59.8x) compared to the Healthcare Services industry average (35.1x).
PE vs Market: COV is poor value based on its PE Ratio (59.8x) compared to the Norwegian market (15.4x).
Price to Earnings Growth Ratio
PEG Ratio: COV is good value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: COV is overvalued based on its PB Ratio (11.8x) compared to the XE Healthcare Services industry average (4.3x).
Next Steps
Future Growth
How is ContextVision forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
61.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COV's forecast earnings growth (61.3% per year) is above the savings rate (0.7%).
Earnings vs Market: COV's earnings (61.3% per year) are forecast to grow faster than the Norwegian market (18.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: COV's revenue (24.8% per year) is forecast to grow faster than the Norwegian market (3.3% per year).
High Growth Revenue: COV's revenue (24.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: COV's Return on Equity is forecast to be low in 3 years time (11.7%).
Next Steps
Past Performance
How has ContextVision performed over the past 5 years?
-8.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: COV has a high level of non-cash earnings.
Growing Profit Margin: COV became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: COV's earnings have declined by -8.8% per year over the past 5 years.
Accelerating Growth: COV has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: COV has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.4%).
Return on Equity
High ROE: COV's Return on Equity (19.7%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is ContextVision's financial position?
Financial Position Analysis
Short Term Liabilities: COV's short term assets (SEK58.0M) exceed its short term liabilities (SEK24.3M).
Long Term Liabilities: COV's short term assets (SEK58.0M) exceed its long term liabilities (SEK6.6M).
Debt to Equity History and Analysis
Debt Level: COV is debt free.
Reducing Debt: COV has not had any debt for past 5 years.
Debt Coverage: COV has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: COV has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: COV has a low level of unsold assets or inventory.
Debt Coverage by Assets: COV's debt is covered by short term assets (assets are 3.26370235496E+16x debt).
Next Steps
Dividend
What is ContextVision's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate COV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate COV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if COV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if COV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: COV is not paying a notable dividend for the Norwegian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of COV's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Fredrik Palm 0
0.8yrs
Tenure
Mr. Fredrik Palm has been the Chief Executive Officer of ContextVision AB (publ) since April 1, 2019. He was Vice President of Sales at ContextVision AB (publ) since January 2012 until April 1, 2019. He se ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Director | 23.1yrs | kr1.78m | 10.83% SEK83.2m | |
| Co-Founder & Director | 0yrs | no data | 11.09% SEK85.2m | |
| Chief Executive Officer | 0.8yrs | no data | no data | |
| Chief Financial Officer | 4.8yrs | no data | no data | |
| Chief Technical Officer | 0.3yrs | no data | no data | |
| DPA President | 1.1yrs | no data | no data |
1.0yrs
Average Tenure
Experienced Management: COV's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Director | 23.1yrs | kr1.78m | 10.83% SEK83.2m | |
| Co-Founder & Director | 0yrs | no data | 11.09% SEK85.2m | |
| Director | 1.1yrs | no data | no data | |
| Independent Director | 9.1yrs | kr200.00k | 0.098% SEK750.0k | |
| Digital Pathology Advisory Board Member | 2.3yrs | no data | no data | |
| Chairman of the Board | 10.1yrs | kr300.00k | 0.059% SEK450.0k | |
| Digital Pathology Advisory Board Member | 0yrs | no data | no data | |
| Digital Pathology Advisory Board Member | 2.3yrs | no data | no data | |
| Digital Pathology Advisory Board Member | 0yrs | no data | no data | |
| Digital Pathology Advisory Board Member | 0yrs | no data | no data |
5.7yrs
Average Tenure
65yo
Average Age
Experienced Board: COV's board of directors are considered experienced (5.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
ContextVision AB (publ)'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: ContextVision AB (publ)
- Ticker: COV
- Exchange: OB
- Founded: 1983
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: kr767.767m
- Shares outstanding: 7.68m
- Website: https://www.contextvision.com
Number of Employees
Location
- ContextVision AB (publ)
- Klara Norra Kyrkogata 31
- Stockholm
- Stockholm County
- 111 22
- Sweden
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| COV | OB (Oslo Bors) | Yes | Common Shares | NO | NOK | Mar 1997 |
| COVO | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Common Shares | GB | NOK | Mar 1997 |
Biography
ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers worldwide. It operates through two segments, Medical Imaging and Digital Pathology. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Its products include US PLUSView, an image enhancement software product for women’s health, general imaging, cardiovascular, and point of care applications; VolarView, an image enhancement software for the handheld ultrasound market segment; GOPiCE, a technology for volumetric image enhancement in real-time; and REALiCE, a volume enhancement and rendering solution for visualization. The company also provides Altumira/Altumira Plus, a solution for various digital radiography systems; GOPView XR2Plus for x-ray systems for human and veterinary examinations; Orthopedic Package for orthopedic imaging; and GOPView iRVUltra, a software for noise suppression, edge, and contrast enhancement in real time. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI; GOPView Mammo3, an image enhancement software for screening and diagnostic mammography; and INIFY Prostate, an AI-based software that outlines and quantifies suspected cancerous areas in a series of prostate biopsies. ContextVision AB (publ) was founded in 1983 and is headquartered in Stockholm, Sweden.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/18 20:48 |
| End of Day Share Price | 2020/02/18 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.